Cara Therapeutics (CARA) Stock Price, News & Analysis

Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Key Stats

• Today's Range: N/A
• 50-Day Range: $13.29 to $17.10
• 52-Week Range: N/A
• Volume: 237,144 shs
• Average Volume: 24,257 shs
• Market Capitalization: $24.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $72.00
• Consensus Rating: Hold

Cara Therapeutics Stock Analysis - MarketRank™

Cara Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 808th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Cara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cara Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CARA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cara Therapeutics does not currently pay a dividend.

Dividend Growth

Cara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.39

Short Interest

There is no current short interest data available for CARA.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cara Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cara Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Cara Therapeutics is held by insiders.

Percentage Held by Institutions

44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CARA Stock Analysis - Frequently Asked Questions

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) released its earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($13.32) earnings per share for the quarter, missing analysts' consensus estimates of ($9.72) by $3.60. The biopharmaceutical company earned $0.99 million during the quarter, compared to analysts' expectations of $1.26 million. Cara Therapeutics had a negative net margin of 1,099.76% and a negative trailing twelve-month return on equity of 367.97%.

When did Cara Therapeutics' stock split?

Cara Therapeutics shares reverse split on the morning of Wednesday, April 16th 2025. The 1-3 reverse split was announced on Monday, April 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' top institutional investors include Simplex Trading LLC. Insiders that own company stock include Christopher Posner, Frederique PhD Menzaghi, Scott Terrillion, Joana Goncalves, Martin Vogelbaum and Jeffrey L Ives.
View institutional ownership trends.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include LIONS GATE ENTERTAINMENT CORP /CN/ (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CARA
• CIK: 1346830
• Web: www.caratherapeutics.com
• Phone: (203) 406-3700
• Fax: 203-567-1510
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $72.00
• High Stock Price Target: $180.00
• Low Stock Price Target: $36.00
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($21.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-118,510,000.00
• Net Margins: -1,099.76%
• Pretax Margin: -1,099.76%
• Return on Equity: -367.97%
• Return on Assets: -107.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.77
• Quick Ratio: 4.71

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.58 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,574,000
• Free Float: 4,429,000
• Market Cap: $24.33 million
• Optionable: Optionable
• Beta: 0.41